Drugs / TRIMELVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06556004 | May 2021 → Dec 2023 | melanoma | University of Chile | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRIMELVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556004 ↗ |
| Route | Subcutaneous | “TRIMELVax was administered subcutaneously every four weeks for a total of four doses.” PMID 42062531 ↗ Apr 2026 |